Design Therapeutics, Inc. (DSGN) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
DSGN currently has 61.4M outstanding shares. with moderate dilution risk from 23.5M authorized shares representing 38.3% potential dilution. The company has minimally diluted shareholders by 8.58% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 28, 2026 |
10-Q filing | 61.4M shares outstanding |
61M | 24M |
| Mar 09, 2026 |
10-K filing | 57.3M shares outstanding |
57M | 24M |
| Nov 05, 2025 |
10-Q filing | 57.0M shares outstanding |
57M | 24M |
| Aug 07, 2025 |
10-Q filing | 56.9M shares outstanding |
57M | 24M |
| May 07, 2025 |
10-Q filing | 56.8M shares outstanding |
57M | 24M |
| May 07, 2025 |
S-3 filing: The company intends to offer and sell up to $300,000,000 of any combination of shares of its common stock, shares of its preferred stock, debt securities and warrants. |
57M | 24M |
| Mar 10, 2025 |
10-K filing | 56.6M shares outstanding |
57M | 24M |
| Nov 07, 2024 |
10-Q filing | 56.6M shares outstanding |
57M | 24M |
| Aug 05, 2024 |
10-Q filing | 56.6M shares outstanding |
57M | 24M |
| May 08, 2024 |
10-Q filing | 56.5M shares outstanding |
56M | 24M |
| Mar 19, 2024 |
10-K filing | 56.0M shares outstanding |
56M | 24M |
| Nov 13, 2023 |
10-Q filing | 56.0M shares outstanding |
56M | 24M |
| Aug 14, 2023 |
10-Q filing | 55.9M shares outstanding |
56M | 24M |
| May 09, 2023 |
10-Q filing | 55.9M shares outstanding |
56M | 24M |
| Mar 14, 2023 |
10-K filing | 55.7M shares outstanding |
56M | 24M |
| Nov 03, 2022 |
10-Q filing | 55.8M shares outstanding |
56M | 24M |
| Aug 08, 2022 |
10-Q filing | 55.7M shares outstanding |
56M | 24M |
| May 09, 2022 |
10-Q filing | 55.8M shares outstanding |
56M | 24M |
| Apr 27, 2022 |
S-3 filing: The company may offer and sell up to $300,000,000 of any combination of shares of our common stock, shares of our preferred stock, debt securities and warrants to purchase any of such securities, in one or more offerings as described in this prospectus. |
56M | 24M |
| Mar 10, 2022 |
10-K filing | 55.7M shares outstanding |
56M | 0 |
| Nov 09, 2021 |
10-Q filing | 55.7M shares outstanding |
56M | 0 |
| Aug 09, 2021 |
10-Q filing | 55.6M shares outstanding |
56M | 0 |
| May 10, 2021 |
10-Q filing | 55.6M shares outstanding |
56M | 0 |
| Mar 22, 2021 |
S-1/A filing: The document is an S-1/A filing related to Design Therapeutics, Inc. and includes details regarding a proposed equity incentive plan and the company's capital structure, including shares outstanding and potential dilution from stock options and future equity issuances. |
42M | 0 |